Supplemental Materials

Force field parameters for naproxen

To parameterize naproxen we used standard CHARMM19 atom types. The charges were assigned consistent with the standard charges in the CHARMM19 force field and SASA implicit solvent model. Charges in the methoxy group were assigned using the parameterization of trimethoprim molecule [1]. The bond length and bond angle terms were autogenerated. The dihedral and improper angle potentials were transferred from structurally analogous amino acids Glu and Val (for carboxylate group in naproxen), Phe and Trp (for naphthalene ring), and Tyr (for methoxy group). Additional improper angle for C14 atom (Fig. 1c in the paper) was introduced as in branched side chain of Ile. The topology description of naproxen molecule in CHARMM19 force field is given below:

RESI NPXN	0.00000 ! naproxen
! / ! C8 ! ! C3 ! / \ ! C102	C7 C12 C14 C7 C12 C14 C6 C11-C13-C15016 C5 C10 017 C4 C9
GROUP ATOM C1 CH ATOM O2 OS	13E 0.15 -0.30
ATOM C3 CR GROUP ATOM C4 CR	0.15 ALE 0.00
ATOM C5 CR ATOM C6 CR ATOM C7 CR	0.00 0.00 0.00 0.00
ATOM C8 CR ATOM C9 CR	1E 0.00 1E 0.00
ATOM C10 CR ATOM C11 CR ATOM C12 CR	x 0.00 x1E 0.00
GROUP ATOM C13 CH ATOM C14 CH	11E -0.15 13E 0.00
ATOM C15 C ATOM 016 OC ATOM 017 OC	1.35 -0.60 -0.60

BOND C1 BOND C6 BOND C1 BOND C1	02 C7 0 C11 3 C15		02 C7 C11 C15	C3 C8 C12 O16	C3 C8 C12 C15	C4 C3 C6 O17		C4 C5 C11	C5 C9 C13		C5 C9 C13	C6 C10 C14
DIHE C4 DIHE C1 DIHE C4 DIHE C8	C3 1 C13 C5 C6	02 C15 C6 C5	C1 017 C12 C10	C12 C7 C8	C11 C6 C5	C13 C5 C6	C15 C9 C11					
IMPH C3 IMPH C1 IMPH C3 IMPH C6 IMPH C5 IMPH C1	C4 5 016 C4 C7 C9 1 C12	C8 017 C5 C8 C10 C6	02 C13 C6 C3 C11 C5	C13 C11 C4 C7 C9 C12	C15 C10 C5 C8 C10 C6	C14 C12 C6 C3 C11 C5	C11 C13 C7 C4 C12 C9		C5 C8 C10 C6	C6 C3 C11 C5	C7 C4 C12 C9	C8 C5 C6 C10
IC C1 IC O2 IC C3 IC C4 IC C5 IC C10 IC C9 IC C5 IC C6 IC C5 IC C10 IC C12 IC C11 IC C11 IC C13	02 C4 C5 C6 C9 C5 C6 C4 C7 C12 C11 C15 C13 O16	C3 *C3 C5 C6 C7 C5 C6 C12 *C5 *C6 *C11 C13 *C13 C15 *C15	C4 C8 C6 C7 C8 C6 C12 C11 C9 C12 C13 C15 C14 O16 O17	0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000	$\begin{array}{c} 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 &$	0 18 0 18 0 0 0 0 0 0 0 18 0 18 0 18 0 1	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	000. 000. 000. 000. 000. 000. 000. 000	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	

The following parameters for bond, dihedral and improper angle potentials were added:

ANGL	ES								
CR1E	CR	CH1E	70.	0	121.	. 5			
CR	CH1E	С	70.	0	112.	. 5			
CR	CH1E	CH3E	70.	0	106.	. 5			
CR	CR1E	CR	90.	0	119.	. 0			
CR	OS	CH3E	46.	5	120.	. 5			
CR1E	CR	OS	65.	0	119.	. 0			
DIHE									
CR1E	CR	CH1E	С	1.	6		3	0.0	
CR1E	CR	OS	CH3E	1.	8		2	180.0	
IMPH	Ι								
CR	CR1E	CR1E	CH1E	90.	0	0	0.0		
CH1E	С	CH3E	CR	55.	0	0	35.20	5439	
CR	CR1E	CR1E	OS	150.	0	0	0.0		

The solvation parameters for ester OS atom were set equal to those of hydroxyl oxygen. The transferred intramolecular terms in CHARMM19 were checked by building the naproxen molecule by analogy in the all-atom CHARMM general force field [2]. The energy minimized structures in both force fields were very similar (RMSD ~ 0.35 Å).

Convergence of REMD simulations

The convergence of REMD sampling of A β -naproxen interactions was tested using the number N_s of the unique states (E_{eff}, L_e) sampled at least once in the course of simulations. Each state (E_{eff}, L_e) is defined by the effective energy of the simulation system, E_{eff} , which includes the potential and solvation energies, and by the number of ligands L_e bound to the fibril edge e=CX or CV (Fig. 1b). Fig. S1 shows N_s as a function of the cumulative equilibrium simulation time τ_{sim} . As τ_{sim} exceeds roughly 10 µs N_s levels off suggesting the onset of approximate convergence of REMD simulations. The convergence of A β -naproxen simulations is very similar to that observed in our previous simulations of binding ibuprofen molecules to A β fibril (ref. [35] in the paper).



Fig. S1 The numbers of unique states N_s sampled in the course of REMD simulations as a function of cumulative equilibrium simulation time τ_{sim} . The solid and dashed lines correspond to N_s computed for the naproxen molecules bound to different edges of A β fibril.

To further test the reliability of REMD sampling we divided the simulation data into two equal subsets and analyzed them independently. The thermodynamic quantities from the two subsets related to naproxen interactions with A β fibril differed by no more than 8% from the averages computed using the entire dataset. The quantities related to naproxennaproxen interactions have the errors not exceeding 10%. The convergence of A β -ibuprofen REMD simulations is reported in ref. [35] in the paper.

Testing force field parameterization of naproxen

Bednarek *et al* have performed the conformational analysis of naproxen using *ab initio* methods and NMR technique at 300K (ref. [52] in the paper). Among the quantities considered were the distributions of two dihedral angles ϕ and χ . These angles are defined by the atoms C12-C11-C13-C15 and C1-O2-C3-C4 in Fig. 1c. Theoretical analysis of naproxen revealed three peaks in the distribution of ϕ at \approx -116°, \approx -43° and \approx 126° with the populations of 0.11, 0.18, and 0.70. The distribution of χ dihedral angle has a single maximum at \approx -3° with the population of 0.8. The existence of three states in the distribution of ϕ dihedral angle was supported by NMR data. To test naproxen parameterization in CHARMM19 force field we computed the probability distributions $P(\phi)$ and $P(\chi)$ at 330K, i.e., at the lowest temperature at which conformational states were collected in REMD. Fig. S2 shows that $P(\phi)$ has three maxima, at \approx -175° and \approx -43°, and \approx 58°. The populations of these states are 0.06, 0.14, and 0.80, respectively. According to Fig. S2 the distribution $P(\chi)$ has two peaks of equal amplitude at \approx -180° and \approx -6°.

When compared against ab initio data CHARMM19 force field reproduces the number of peaks in $P(\phi)$ and approximately their location. Our parameterization of naproxen also correctly predicts the statistical weights of the three peaks. The largest discrepancy between our and *ab initio* results is the location of the dominant peak #3. The impact of this difference on ligand binding can be assessed using our previous simulations of ibuprofen binding to A β fibril (ref. [35] in the paper and unpublished data). Ibuprofen has chemically identical group G3 (Fig. 1c) with the equivalent dihedral angle ϕ formed by C3-C4-C7-C8. For ϕ we have tested two versions of dihedral angle potential, first with zero amplitude (which facilitates free rotation around ϕ) and the second identical to the one used in naproxen. These potentials result in sharply different distributions $P(\phi)$ at 330K. The first leads to the appearance of two peaks of equal height at \approx -120° and \approx 60°. The second results in the distribution almost identical to that in Fig. S2. Interestingly, differences in the parameterizations have negligible impact on binding to AB fibril. For example, the numbers of ligands bound to the fibril CX and CV edges vary between the parameterizations by 4 and 1%, respectively. The difference in the free energy of binding is less than 1%. These findings suggest that the exact location of the maximum #3 in $P(\phi)$ should not significantly affect naproxen binding to Aβ fibril.

The peak #1in the distribution $P(\chi)$ computed from our simulations (Fig. S2) coincides with that obtained from *ab initio* calculations (ref. [52] in the paper). However, CHARMM19 simulations predict the existence of the second maximum of equal amplitude that is at variance with the *ab initio* data. It is worth noting that our energetics analysis (see Results) suggests that the group G2 plays minor role in naproxen binding compared to G1 or G3. Therefore, the specific form of the distribution $P(\chi)$ is not likely to be important for naproxen binding to A β fibril. A reasonable agreement between the conformational ensembles obtained from *ab initio* calculations and our simulations supports the CHARMM19 parameterization of naproxen.



Fig. S2 Probability distributions, $P(\phi)$ and $P(\chi)$, of naproxen dihedral angles ϕ and χ (Fig. 1c) computed at 330K. $P(\phi)$ and $P(\chi)$ serve as tests of the naproxen parameterization. The distributions $P(\phi)$ and $P(\chi)$ are computed for all naproxen molecules irrespective of their binding state. We checked that binding has a minor impact on these distributions that allows us to directly compare them with the ab *initio* dihedral angle distributions computed for a single molecule.

Distribution of ibuprofen on the fibril edges

To compare binding of naproxen and ibuprofen we computed the distributions of bound ibuprofen molecules $\langle L(S_c) \rangle$ at 360K (Fig. S3). In contrast to naproxen (Fig. 4b) ibuprofen tends to form small clusters upon binding to A β fibril. The numbers of ligands bound to the CV and CX edges are $\langle L_{CV} \rangle \approx 13.5$ and $\langle L_{CX} \rangle \approx 12.1$, of which 5.8 and 3.0 are included in large clusters. Therefore, the fractions of ibuprofen molecules forming large clusters are $\phi_{CV}=0.43$ and $\phi_{CX}=0.25$.



Fig. S3 Distributions of the numbers of bound ibuprofen ligands $\langle L(S_c) \rangle$ with respect to cluster size S_c on the CX and CV edges.

Binding mechanism for modified naproxen

To provide direct test of the importance of interligand interactions for binding we performed simulations of modified naproxen. We used the same simulation system as described in Materials and Methods with the exception that all non-bonded interactions between naproxen molecules were switched off. This modification of energy function radically changes naproxen binding. The binding temperature is reduced from 398K to <330K and the difference in edge binding affinities is eliminated. Fig. S4 compares the numbers of ligands bound to the CV and CX edges, $\langle L_{CV} \rangle$ and $\langle L_{CX} \rangle$, for the original and modified naproxen ligands. It is seen that cancelation of non-bonded interligand interactions erases the difference between $\langle L_{CV} \rangle \approx 8.5$. Furthermore, the cluster distributions $\langle L(S_c) \rangle$ for the modified naproxen become unimodal, because the formation of large clusters is completely blocked ($\phi_{CV} = \phi_{CX} \approx 0$). These findings strengthen our conclusion that the interligand interactions are one of the two key factors controlling binding.



Fig. S4 The numbers of naproxen molecules $\langle L \rangle$ bound to the CV and CX edges vs temperature. The data for the naproxen ligands, in which non-bonded interligand interactions are switched off, are shown in black: thin and dashed lines represent $\langle L \rangle$ computed for the CV and CX. The data in grey represent the "original" naproxen simulations (as shown in Fig. 3a): thick and thin lines mark binding to the CV and CX edges. The plot suggests that cancelation of interligand interactions makes binding affinities of the edges equal.

Ordering of bound naproxen molecules

To check mutual ordering of naproxen ligands, which may occur upon binding to the fibril, we computed the probability distribution $P(cos(\phi))$ of the angles ϕ formed by naphthalene rings. To this end, for each bound naproxen molecule we define a vector \vec{n} , which is the cross product of the vectors $\vec{r}_1 = \vec{R}(C11) \cdot \vec{R}(C3)$ and $\vec{r}_2 = \vec{R}(C10) \cdot \vec{R}(C8)$,

where \vec{R} are the radius vectors of naproxen carbon atoms (Fig. 1c). Due to planarity of naphthalene ring \vec{n} describes its orientation. The angle ϕ is then obtained from the scalar product of the vectors \vec{n}_i and \vec{n}_j computed for the bound naproxen molecules *i* and *j*, which are in contact with each other. The distribution $P(cos(\phi))$ is plotted in Fig. S5.



Fig. S5 Probability distribution $P(cos(\phi))$ of the angles ϕ for the pairs of interacting naproxen molecules bound to the fibril. The plot suggests that parallel alignment of naproxen molecules is preferred.

References

- Fleischman, S. H. and Brooks, C. L, 1990. Protein-Drug interactions: Characterization of inhibitor binding in complexes of DHFR with trimethoprim and related derivatives. *Proteins Struct. Funct. Bioinform.* 7, 52-61.
- [2] Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., MacKerell, A. D., Jr., 2010. CHARMM General Force Field (CGenFF): A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. *J. Comp. Chem.* **31**, 671-690.